GR 103691CAS# 162408-66-4 |
- GPR120 modulator 1
Catalog No.:BCC1599
CAS No.:1050506-75-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 162408-66-4 | SDF | Download SDF |
PubChem ID | 4302960 | Appearance | Powder |
Formula | C30H35N3O3 | M.Wt | 485.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | 4-(4-acetylphenyl)-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]benzamide | ||
SMILES | CC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NCCCCN3CCN(CC3)C4=CC=CC=C4OC | ||
Standard InChIKey | JARNORYOPMINDY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A potent and selective dopamine D3 receptor antagonist, with a Ki value of 0.3 nM and > 100- fold selectivity over D2 and D4 sites. |
GR 103691 Dilution Calculator
GR 103691 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0592 mL | 10.2959 mL | 20.5918 mL | 41.1836 mL | 51.4795 mL |
5 mM | 0.4118 mL | 2.0592 mL | 4.1184 mL | 8.2367 mL | 10.2959 mL |
10 mM | 0.2059 mL | 1.0296 mL | 2.0592 mL | 4.1184 mL | 5.148 mL |
50 mM | 0.0412 mL | 0.2059 mL | 0.4118 mL | 0.8237 mL | 1.0296 mL |
100 mM | 0.0206 mL | 0.103 mL | 0.2059 mL | 0.4118 mL | 0.5148 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-Cyclopropylmethoxy-4-difluoromethoxybenzoic acid
Catalog No.:BCC8628
CAS No.:162401-62-9
- Roflumilast
Catalog No.:BCN2182
CAS No.:162401-32-3
- 3-O-Methyl-Estrone
Catalog No.:BCC8640
CAS No.:1624-62-0
- Vibralactone L
Catalog No.:BCN6914
CAS No.:1623786-67-3
- Vibralactone K
Catalog No.:BCN6746
CAS No.:1623786-66-2
- 3-Amino-3-(hydroxymethyl)-1-(4-octylphenyl)-1,4-butanediol
Catalog No.:BCN1541
CAS No.:162361-49-1
- Fingolimod hydrochloride
Catalog No.:BCN2167
CAS No.:162359-56-0
- 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol
Catalog No.:BCN1542
CAS No.:162359-55-9
- Acetamide, N-[1,1-bis[(acetyloxy)methyl]-3-(4-octylphenyl)propyl]-
Catalog No.:BCN2254
CAS No.:162358-09-0
- Diethyl 2-acetamido-2-(4-octylphenethyl)malonate
Catalog No.:BCN1543
CAS No.:162358-08-9
- 1-(2-iodoethyl)-4-octylbenzene
Catalog No.:BCN2253
CAS No.:162358-07-8
- Benzeneethanol, 4-octyl
Catalog No.:BCN2255
CAS No.:162358-05-6
- Stilbostemin B
Catalog No.:BCN4697
CAS No.:162411-67-8
- VR23
Catalog No.:BCC6523
CAS No.:1624602-30-7
- Subelliptenone G
Catalog No.:BCN1720
CAS No.:162473-22-5
- Salirasib
Catalog No.:BCC1918
CAS No.:162520-00-5
- CDP 840 hydrochloride
Catalog No.:BCC7814
CAS No.:162542-90-7
- Fmoc-Dap(Boc)-OH
Catalog No.:BCC3188
CAS No.:162558-25-0
- Broussoflavonol F
Catalog No.:BCN3571
CAS No.:162558-94-3
- 3-Hydroxy-5,7-dimethoxy-3',4'-methylenedioxyflavan
Catalog No.:BCN1540
CAS No.:162602-04-2
- Isolupalbigenin
Catalog No.:BCN6835
CAS No.:162616-70-8
- Eriosemation
Catalog No.:BCN3738
CAS No.:162616-72-0
- Sorokinianin
Catalog No.:BCN6978
CAS No.:162616-73-1
- Temsirolimus
Catalog No.:BCC3678
CAS No.:162635-04-3
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.[Pubmed:9765337]
J Pharmacol Exp Ther. 1998 Oct;287(1):187-97.
The benzofurane (+)-S 14297, the benzamide nafadotride, the aminoindane U 99194 and the arylpiperazine GR 103,691 have been proposed as "selective" antagonists at dopamine D3 vs. D2 receptors. Herein, we compared their in vitro affinities and in vivo actions to those of the aminotetralin D3 antagonists (+)-AJ 76 and (+)-UH 232. Affinities at recombinant, human (h)D3 and/or hD2 sites were determined by employing the mixed D2/D3 antagonist [125I]-iodosulpride and the preferential D3 ligands [3H]-(+)-PD 128, 907 and [3H]-(+)-S 14297. [3H]-(+)-PD 128,907, [3H]-(+)-S 14297 and [125I]-iodosulpride yielded an essentially identical pattern of displacement at D3 sites, which suggests that they recognize the same population of receptors. The rank order of potency (Ki values in nM vs. [3H]-(+)-PD 128,907) was GR 103,691 (0.4) approximately nafadotride (0.5) > haloperidol (2) approximately (+)-UH 232 (3) approximately (+)-S 14297 (5) > (+)-AJ 76 (26) > U 99194 (160). The rank order of preference (Ki ratio, D2:D3) for D3 receptors (labeled by [3H]-PD 128,907) vs. D2 sites (labeled by [125I]-iodosulpride) was (+)-S 14297 (61) approximately GR 103,691 (60) > U 99194 (14) > nafadotride (9) approximately (+)-UH 232 (8) approximately (+)-AJ 76 (6) > haloperidol (0.2). (+)-S 14297 and GR 103,691 also showed greater than 100-fold selectivity at dopamine hD3 vs. hD4 and hD1 sites. However, GR 103,691 showed marked affinity for serotonin1A receptors (5.8 nM) and alpha-1 adrenoceptors (12.6 nM). In vivo, all antagonists except GR 103,691 prevented the induction of hypothermia by (+)-PD 128,907 (0.63 mg/kg s.c.) and a further preferential D3 agonist, (+)-7-OH-DPAT (0.16 mg/kg s.c.). On the other hand, haloperidol, (+)-AJ 76, (+)-UH 232 and nafadotride all induced catalepsy in rats, whereas (+)-S 14297, U 99194 and GR 103,691 were inactive. Haloperidol, (+)-AJ 76, (+)-UH 232, nafadotride and (weakly) U 99194 also enhanced prolactin secretion and striatal dopamine synthesis, whereas (+)-S 14297 and GR 103,691 were inactive. However, despite its high affinity at 5-HT1A receptors and alpha-1 adrenoceptors, both of which are present on raphe-localized serotonergic neurons, GR 103,691 (0.5 mg/kg i.v.) failed to influence their basal firing rate or the inhibition of their electrical activity by the 5-HT1A agonist (+/-)-8-OH-DPAT (0.005 mg/kg i.v.), a result that casts doubt on its activity in vivo. In conclusion, both (+)-S 14297 and GR 103,691 are markedly selective ligands that permit the characterization of actions at hD3 vs. hD2 receptors in vitro, but (+)-S 14297 appears to be of greater utility for the evaluation of their functional significance in vivo. Nevertheless, to develop a better understanding of the respective roles of dopamine D3 and D2 receptors, we need additional, chemically diverse antagonists of improved potency and selectivity.